BioCentury
ARTICLE | Company News

FDA panel backs Nuplazid

March 30, 2016 1:31 AM UTC

Members of FDA's Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12-2 that the benefits outweigh the risks of Nuplazid pimavanserin from Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) to treat Parkinson's disease psychosis (PDP).

The committee also voted 12-2 that Acadia provided substantial evidence of the small molecule serotonin (5-HT2A) receptor inverse agonist's efficacy, and 11-3 that it had adequately characterized the therapy's safety profile. ...